Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

MRD and Acute Lymphoblastic Leukemia

View overview page
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
3:52
Maintenance therapy with revumenib following alloSCT in KMT2Ar and NPM1-mutated acute leukemias
Andrius Žučenka • 8 Dec 2023
3:54
A case study from the ECOG-E1910 trial: early blinatumomab treatment in ALL
Mark Litzow • 27 Feb 2024
4:20
Therapy-related ALL: etiology, prognosis, and treatment
Caner Saygin • 19 Jan 2024
2:41
Assessing the prognostic value of NGS-based MRD in adults with ALL undergoing SCT
Emily Liang • 10 Dec 2023
0:44
Is HSCT a suitable treatment option for patients with ALL who have achieved undetectable BCR::ABL1?
Mark Litzow • 10 Dec 2023
1:54
Final results of the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph- B-ALL
Sabina Chiaretti • 10 Dec 2023
1:28
Venetoclax & dose-reduced chemotherapy for the treatment of older adults with B-ALL and T-ALL
Marlise Luskin • 10 Dec 2023
2:34
Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial
Marlise Luskin • 10 Dec 2023
4:06
AUGMENT-101 trial: revumenib in patients with R/R KMT2Ar acute leukemia
Ibrahim Aldoss • 11 Dec 2023
2:09
Predictors of achieving undetectable BCR::ABL1 in patients with ALL
Mark Litzow • 10 Dec 2023
1:03
ECOG-E1910 study: clinical benefit of early blinatumomab incorporation in ALL
Bijal Shah • 8 Sep 2023
1:59
Novel CAR-T constructs being investigated for the treatment of ALL
Nitin Jain • 7 Sep 2023
2:30
The importance of MRD-guided therapy in ALL
Nicholas Short • 6 Sep 2023
2:40
The role of PCR and NGS-based MRD in Ph+ ALL
Nicholas Short • 6 Sep 2023
1:10
The challenge of persistent MRD in T-ALL & novel approaches being explored
Caner Saygin • 7 Sep 2023
The content of VJHemOnc is intended for healthcare professionals